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Abstract 186 
Background 187 
In vitro and observational epidemiological studies suggest that vitamin D may play a role in 188 
cancer prevention. However, the relationship between vitamin D and ovarian cancer is 189 
uncertain, with observational studies generating conflicting findings. A potential limitation 190 
of observational studies is inadequate control of confounding. To overcome this problem, 191 
we used Mendelian randomization (MR) to evaluate the association between single 192 
nucleotide polymorphisms (SNPs) associated with circulating 25-hydroxyvitamin D 193 
(25(OH)D) concentration and risk of ovarian cancer. 194 
Methods 195 
We employed SNPs with well-established associations with 25(OH)D concentration as 196 
instrumental variables for MR: rs7944926 (DHCR7),  rs12794714 (CYP2R1) and rs2282679 197 
(GC). We included 31 719 women of European ancestry (10 065 cases, 21 654 controls) from 198 
the Ovarian Cancer Association Consortium, who were genotyped using customized Illumina 199 
Infinium iSelect (iCOGS) arrays. A two-sample (summary data) Mendelian randomization 200 
approach was used, and analyses were performed separately for all ovarian cancer (10 065 201 
cases) and for high-grade serous ovarian cancer (4 121 cases).  202 
Results 203 
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The odds ratio for epithelial ovarian cancer risk (10 065 cases) estimated by combining the 204 
individual SNP associations using inverse variance weighting was 1.27 (95% confidence 205 
interval: 1.06 to 1.51) per 20nmol/L decrease in 25(OH)D concentration. The estimated odds 206 
ratio for high-grade serous epithelial ovarian cancer (4 121 cases) was 1.54 (1.19, 2.01).  207 
Conclusions 208 
Genetically lowered 25-hydroxyvitamin D concentrations were associated with higher 209 
ovarian cancer susceptibility in Europeans. These findings suggest that increasing plasma 210 
vitamin D levels may reduce risk of ovarian cancer.  211 
  212 Key Messages 
• Previous observational studies have reported conflicting findings on the 
association between serum 25(OH)D concentration and ovarian cancer. 
• Results from this study suggest that lower 25(OH)D concentration associates 
with higher susceptibility to ovarian cancer. 
• Among different ovarian cancer subtypes, the magnitude of association was 
the highest for high-grade serous ovarian cancer. 
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Introduction 213 
Ovarian cancer is one of the most fatal cancers among women [1]. Survival following 214 
diagnosis is poor (less than 50% at 5 years post-diagnosis) with a mortality rate of 152 000 215 
per year worldwide [2, 3]. The most common histological subtype is serous carcinoma 216 
(further classified into high grade serous and low grade serous); other subtypes include 217 
mucinous, clear cell and endometrioid carcinomas [4]. Higher parity and oral contraceptive 218 
use reduce risk while established risk factors include a history of endometriosis, obesity and 219 
family history of ovarian or breast cancer [5]. Several recent studies have examined whether 220 
or not serum 25-hydroxyvitamin D (25(OH)D) concentrations are associated with ovarian 221 
cancer risk or mortality [6-12]. 222 
 223 
Vitamin D is produced in the skin when 7-dehydrocholesterol is exposed to UVB. It is 224 
transported to the liver where it is hydroxylated to become 25(OH)D. It then undergoes a 225 
second hydroxylation step, primarily in the liver, to become the active form, 1,25-226 
dihydroxyvitaminD (calcitriol). While 25(OH)D is relatively inactive, it has a long half-life and 227 
its production is loosely regulated, making it a useful indicator of vitamin D status. In vitro 228 
and animal studies suggest that calcitriol has a variety of anti-cancer effects, including the 229 
prevention of cell disjunction [13-16], preventing overgrowth and exerting multiple anti-230 
proliferative and anti-inflammatory effects [17].   231 
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 232 
The association between vitamin D and ovarian cancer is controversial. Most recent 233 
observational studies found no strong evidence for an association between circulating 234 
25(OH)D and risk for this cancer [7, 8, 10, 18-20]. One limitation of these studies is that their 235 
findings may only be generalized for specific populations because of the latitudes in which 236 
they were conducted. Furthermore, the variety of different 25(OH)D measurement 237 
techniques as well as the different subtype distribution of ovarian cancers used in the 238 
various studies might have also affected the results [8]. More fundamentally, a limitation of 239 
observational studies is that confounding and reverse causation can make it difficult to 240 
interpret the results. For example, affected individuals may have altered vitamin D levels 241 
due to their disease status. Randomized clinical trials (RCT) are an attractive alternative to 242 
observational studies as these remove biases from confounding and reverse causation. 243 
However, RCTs are costly and logistically cumbersome, and there are no published RCTs 244 
assessing the relationship between 25(OH)D levels and risk of epithelial ovarian cancer. 245 
 246 
 Mendelian randomization (MR) is an approach for evaluating associations of an 247 
exposure with a disease [21, 22]. This technique utilises the fact that allelic variants are 248 
assigned at random during meiosis, making them potentially robust and unbiased (free from 249 
confounding effects) instruments to gauge the effect of an exposure (e.g., low vitamin D) on 250 
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a trait (e.g., cancer) [22]. An instrumental variable (SNP) used in a MR study also has to 251 
satisfy the following assumptions [21, 22]: 1) the instrumental variable is associated with 252 
the exposure of interest; 2) the instrumental variable is independent of confounding factors 253 
that might confound the association of the exposure with the outcome; and 3) the 254 
instrumental variable is only associated with the outcome through the exposure (Fig 1). Two 255 
key determinants of the power of an MR study are the variance in the modifiable exposure 256 
explained by the genetic variants (SNPs) and the sample size of the study associating the 257 
relevant SNPs with the trait of interest. To date, SNPs associated with vitamin D level 258 
explain only a very small proportion (approximately 1-4%) of the trait variance. Therefore, 259 
for MR to be informative for vitamin D concentrations, large sample sizes are needed. Here 260 
we use large-scale data from the Ovarian Cancer Association Consortium (OCAC) in an MR 261 
framework to assess whether or not SNPs associated with 25(OH)D concentration are 262 
related to risk of ovarian cancer. 263 
(Fig 1 here: title - Schematic of the Mendelian randomization framework in our study using 264 
vitamin D SNPs as instrumental variables.) 265 
 266 
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Methods 267 
Data sources 268 
Individual level genetic data from the Ovarian Cancer Association Consortium (OCAC) were 269 
used in this study. Participants from 43 studies from around the world were genotyped 270 
using the Illumina Infinium iSelect (iCOGS) array [23]. Quality control was as per previous 271 
work, with related individuals and ancestry outliers removed [4]. We excluded 13 studies of 272 
individuals of non-European ancestry [4], the remaining studies that contributed to our 273 
analysis were listed in Supplementary Table 4. For examination of all histotypes of ovarian 274 
cancer combined, we had 10 065 cases and 21 654 controls for analysis. The distribution of 275 
histological subtypes is shown in Table 1. For high-grade serous ovarian cancer, 4 121 cases 276 
were available. We also performed MR analysis on the other subtypes individually, although 277 
sample sizes were much smaller than for high grade serous cancer. 278 
(Table 1 here) 279 
 280 
SNP selection criteria 281 
 Several SNPs have been observed in association with 25(OH)D concentrations: rs6013897 in 282 
the Cytochrome P450, family 24, subfamily A, polypeptide 1 (CYP24A1) gene; rs2282679 and 283 
rs7041 in the Group-Specific Component (GC) gene ; rs12800438 and rs7944926 near the 7-284 
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Dehydrocholesterol Reductase (DHCR7) gene; and rs10741657 and rs12794714 in the 285 
Cytochrome P450, family 2, subfamily R, polypeptide 1 (CYP2R1) gene [24-30]. The iCOGs 286 
array directly genotyped rs12794714 and rs2282679; rs7944926 was the best imputed 287 
DHCR7 SNPs (imputation quality score of 0.92) described by previous study [31]. We were 288 
unable to include rs6013897 in CYP24A1 as there were no SNPs in adequate linkage 289 
disequilibrium (	>0.3) genotyped on our arrays. These SNPs are potential instrumental 290 
variables with respect to 25(OH)D concentrations. To ensure that these SNPs instruments 291 
can be applied to the MR via summary statistics approach, we first required accurate 292 
25(OH)D association estimates for each of the SNP – the most accurate estimates available 293 
were those from Afzal et al. [31] for the SNPs within/near DHCR7 and CYP2R1, whereas the 294 
estimates for the GC SNP is only available in Mokry et al. [26]. (the effect of the GC SNP on 295 
25(OH)D was only estimated based on 2 347 individuals [26] whereas the estimates for 296 
DHCR7 and CYP2R1 were derived based on 30 792 individuals [31]). We then examined their 297 
associations with various potential confounders using publicly available GWAS datasets (The 298 
complete list of potential confounders that were investigated is available in Supplementary 299 
Table 1). 300 
 301 
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Statistical analyses 302 
 MR operates by comparing the estimated magnitude of the association of the SNPs on the 303 
modifiable risk factor (25(OH)D concentration) with the magnitude of the association of the 304 
SNP on the outcome of interest (ovarian cancer). Estimates of the association of the 305 
relevant SNPs with ovarian cancer status were derived using logistic regressions using 306 
SNPTEST [32]. We adjusted for intra-ethnic (i.e. within Europeans) population differences by 307 
incorporating the first six principal components and indicators for study number as 308 
covariates in the SNP-outcome regressions. To check for evidence of residual population 309 
stratification, we computed the genomic control lambda value from 195,183 directly 310 
genotyped autosomal SNPs genome-wide. Additional confounding variables such as time 311 
spent outdoors, socio-economic status and BMI ere not adjusted in our model as these 312 
information were not available on all individuals in our dataset. Instead, samples with 313 
available confounder data (n < 26 000) were retained for subsequent sensitivity analysis 314 
(See Discussion).  315 
 316 
  In the absence of information on 25(OH)D concentration levels in the OCAC dataset, 317 
we applied a two-sample approach that uses only summary data to assess indirect 318 
associations [33] where estimates for the SNP-outcome associations are from a different 319 
sample than the SNP-exposure associations. Here we obtain 25(OH)D association estimates 320 
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from GWAS summary statistics for SNP instruments that passed the selection criteria 321 
mentioned above. Combining these magnitudes of association, the association of 25(OH)D 322 
concentration levels on ovarian cancer,  the weighted estimate can be computed using the 323 
Wald-type ratio estimator [21]. The weighted model that was used to obtain the 324 
instrumental variable estimates are shown in the supplementary section. Analyses were 325 
performed for all epithelial ovarian cancers irrespective of histological subtype and 326 
separately for high-grade serous epithelial ovarian cancer. To be compatible with previous 327 
studies [31, 34], estimates were scaled to a 20nmol/Liter change in 25(OH)D level; 328 
20nmol/Liter is approximately the inter-tertile range (66
th
 percentile to 33
rd
 percentile) 329 
observed in a large European study [31].  330 
  331 
Results 332 
Validation of instrument strength 333 
We examined each of the MR assumptions in turn. To satisfy the 1
st
 MR assumption our 334 
SNPs must be clearly associated with 25(OH)D concentrations; typically an F-statistic >10 is a 335 
commonly used threshold for a strong instrument. We specifically chose SNPs from DHCR7, 336 
CYP2R1 and GC which have been clearly shown to be associated with 25(OH)D 337 
concentrations. In Afzal et al. [31], the SNPs we use are very strongly associated where the F 338 
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statistics for each SNP is >90. For the GC SNP, the association of this variant with log-339 
transformed 25(OH)D were adequate with a F-statistic of 13.38. The SNPs combined explain 340 
about 1.3% of the variance in 25(OH)D concentration. It is important to note that these 341 
studies were among few of the many studies linking these SNPs to 25(OH)D concentrations 342 
[24, 26, 28, 29, 34]. This evidence combined suggests that the SNPs we used are valid 343 
instruments (i.e. weak instrument bias is not a problem in our study).  344 
 345 
Assessment for pleiotropy 346 
Next we assessed possible pleiotropy. Of the known ovarian cancer risk factors, some have 347 
an established genetic component, with large GWASs conducted. Examining these GWAS 348 
findings, we found no evidence for association between the SNPs in DHCR7 and CYP2R1 and 349 
potential confounders such as smoking behaviour (Supplementary Table 1), hence satisfying 350 
the 2
nd
 MR assumption. We found that neither the lead SNPs, nor any SNPs correlated with 351 
them, were associated with the possible confounders after Bonferroni corrections. For the 352 
other ovarian cancer risk factors (OC use, parity), large scale GWASs have not been 353 
conducted because inherited genetic factors are unlikely to play a major role. The 3
rd
 MR 354 
assumption can be difficult to test directly although the vitamin D metabolism pathway is 355 
well understood and there is substantial evidence that DHCR7 and CYP2R1 play roles in 356 
determining or modulating 25(OH)D concentration [24, 25, 34].   357 
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 358 
Population stratification 359 
 MR analyses are unbiased when they reflect the true relationship between genotype and 360 
phenotype (rather than for example artifactual associations from unmodeled population 361 
structure). Our estimated genomic control lambda value (rescaled to 1 000 cases and 362 
controls) was = 1.005, implying no major effects of population structure. Principal 363 
component analysis showed that the OCAC cases and controls were well matched for 364 
ancestry (Supplementary Figure 2 and 3 in Supplementary material). 365 
 366 
Association of SNPs to 25(OH)D concentration 367 
To estimate the association of the chosen SNPs on 25(OH)D concentrations, we used SNP-368 
25(OH)D association estimates from both published study [26, 31] that were corrected for 369 
seasonal variation. It was shown that the variant rs7944926 near DHCR7 reduced 25(OH)D 370 
concentration levels by 2.0 nmol/Liter per risk allele (A) and the variant rs12794714 in 371 
CYP2R1 reduced 25(OH)D concentration levels by 3.0 nmol/Liter per risk allele (A). Upon 372 
performing conversion of the 25(OH)D estimates from the natural logarithm scale [26], the 373 
variant rs2282679 near GC was shown to reduce 25(OH)D levels by approximately 2.5 374 
nmol/Liter per 25(OH)D decreasing allele (C). 375 
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 376 
Mendelian randomization analysis for all ovarian cancer subtypes 377 
We determined the associations between the 25(OH)D associated SNPs (rs7944926 and 378 
rs12794714) and risk of ovarian cancer  in Table 2. rs12794714 and rs2282679 was directly 379 
genotyped in our dataset, whereas rs7944926 was well imputed (imputation quality score 380 
0.92). For all epithelial ovarian cancer subtypes combined, the estimated magnitude of 381 
association for a 1.0 nmol/Liter change in 25(OH)D level was −0.0076 (standard error (S.E.)= 382 
0.0109) for the MR analysis performed via rs7944926 in DHCR7. This translates into an odds 383 
ratio (OR) of 1.17(0.76-1.78) per 20nmol/Liter decrease in 25(OH)D levels. Similarly, the 384 
magnitude of association was −0.0137, S.E.= 0.0063 for rs12794714 in CYP2R1, with 385 
corresponding OR of 1.31(1.03-1.69) per 20 nmol/Liter decrease in 25(OH)D and the 386 
magnitude of association is -0.0110, S.E.= 0.0082 with OR of 1.25(0.90-1.71) for rs2282679 387 
in GC. Since all these SNPs are independent, a more accurate estimate will be obtained from 388 
the combined associations of the three SNPs. The combined weighted magnitude of 389 
association is −0.0118, with a S.E. of 0.0045. The resultant OR per 20nmol/Liter change in 390 
25(OH)D on all epithelial ovarian cancer subtypes combined is 1.27 (1.06-1.51).  391 
(Table 2 here) 392 
 393 
Page 25 of 43
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
23 
 
 
Mendelian Randomization analysis for high grade serous ovarian cancer 394 
Similar associations were observed between SNPs for 25(OH)D concentration and high 395 
grade serous epithelial ovarian cancer. We obtained a magnitude of association estimate of 396 
−0.0209 (S.E.= 0.0154)  and −0.0257 (S.E.= 0.0091) and −0.0173 (S.E.= 0.0117)  for 397 
rs7944926, rs12794714 and rs2282679 respectively. This resulted in an OR of 1.51(0.83-398 
2.78) using rs7944926, 1.67(1.18-2.38) using rs12794714, and 1.41(0.89-2.23) per 20 399 
nmol/Liter decrease in 25(OH)D. Weighting across all SNP instruments yielded an estimated 400 
magnitude of −0.0218 (S.E.= 0.0067). Hence a 20 nmol/Liter decrease in 25(OH)D 401 
corresponds to an OR of 1.54(1.19-2.01) for high grade serous ovarian cancer.  402 
(Figure 2 here) 403 
(Figure 3 here) 404 
Discussion 405 
Even though the SNPs chosen in our study only explain a small fraction (~1.3%) of the 406 
variance of 25(OH)D concentration, because our case-control sample was so large, we were 407 
able to demonstrate associations with ovarian cancer risk. A genetically scored decrease of 408 
20nmol/Liter of serum 25(OH)D concentration levels, increased the risk of epithelial ovarian 409 
cancer by about 30% in European ancestry women, with a larger association seen in high 410 
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grade serous disease. 411 
 412 
Comparison with previous findings 413 
A recent Danish study [31] used MR to show that low circulating 25(OH)D concentrations 414 
were associated with cancer mortality among Europeans. That study did not separate the 415 
associations of risk and mortality and was underpowered to draw conclusions on any 416 
specific cancer type. Here, for the first time, we demonstrate that for epithelial ovarian 417 
cancer, there is a causal effect of low 25(OH)D concentrations on risk.    418 
 419 
Our results are inconsistent with some previous studies that have reported no 420 
associations between 25(OH)D and ovarian cancer status. The recent meta-analysis [8] of 10 421 
individual cohort studies (884 cases and 1 605 controls) found no association between 422 
25(OH)D concentration and development of ovarian cancer. Findings from epidemiologic 423 
studies may differ from our MR based results because observational studies can be affected 424 
by confounding and reverse causation, though cohort studies such as [8] would be expected 425 
to be less affected. 426 
 427 
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Strength and limitations 428 
A strength of our study is that the mechanism through which our chosen SNPs influence 429 
25(OH)D levels is well understood. DHCR7 encodes the enzyme 7-dehydrocholestrol 430 
reductase, which is responsible for the conversion of 7-dehydrocholestrol to cholesterol. 431 
Reduced activities of 7-dehydrocholestrol reductase, leading to low cholesterol and 432 
accumulation of 7-dehydrocholestrol, are partially attributable to DHCR7 variants [24, 25, 433 
29]. Although rs7944926 lies outside DHCR7, this variant modulates expression of DHCR7 434 
[35]. CYP2R1 is an enzyme which converts vitamin D3 to 25(OH)D in the liver [36], with 435 
rs12794714 unambiguously associated with 25(OH)D concentrations via GWAS [29]. The GC 436 
gene has a primary role in vitamin D transport. Previous studies shown that the rs2282679 437 
variant in particular were also strongly associated (P=4.0×10
42
) with serum vitamin D 438 
binding protein (DBP) based on the study performed on 1 674 individuals in the Twins UK 439 
cohort [29]. The GC variants were also hypothesized to affect bioavailability of vitamin D 440 
through variation in circulating DBP. In view of evidence for its association towards vitamin 441 
D, the rs2282679 SNP is among one of the most associated variant with 25(OH)D (P=1.9×10
-
442 
109
 ) in the SUNLIGHT GWAS [29]. These variants (rs7944926, rs12794714 and rs2282679) 443 
thus affect 25(OH)D levels through varying vitamin D metabolism, bioavailability or 444 
transport, rendering them appropriate instrumental variables for use in MR [26, 27, 31, 34]. 445 
 446 
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  One limitation is that our two-sample MR analysis assumes that the standard error 447 
of the exposure (SNP to 25(OH)D) estimates is negligibly small [33, 37] – given the large 448 
sample size in the Danish study [31], this is a reasonable assumption. In addition, the MR 449 
framework assumes a linear relationship in the association of the SNP instruments on the 450 
underlying exposure. Although our MR estimates indicate that a decrease of 20nmol/Liter in 451 
25(OH)D concentration is associated with a 30% increased risk of epithelial ovarian cancer, 452 
this estimated effect size is derived from a larger sample size of women with a range of 453 
25(OH)D concentrations. Previous studies using MR to examine 25(OH)D concentrations 454 
with different outcomes have dealt with this in various ways. For example, the published 455 
study that we used [31] assumed linearity of change across raw 25(OH)D values. In contrast, 456 
the study by Mokry et al. [26] on vitamin D and multiple sclerosis (MS) considered the 457 
association to be linear on log transformed 25(OH)D.   458 
 459 
 We examined the implications of these approaches by re-computing our findings 460 
based on exposure estimates on the original scale (from the Danish study [31]) and on the 461 
log scale (from MR study on MS [26]) (see Supplementary Table 2). We note that in addition 462 
to the scale differences, the estimates of the magnitude of association of each SNP on 463 
25(OH)D differed due to random sampling error (with estimates from the Danish study [31] 464 
derived from a much larger sample size than those in the MS study [26]). We hence 465 
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repeated our analysis by adopting SNP-exposure estimates used by the MS study [26] for 466 
the SNP rs12785878 (LD to rs7944926 with  = 1.0) in the DHCR7 gene. Although our result 467 
was robust to differences in scaling (log transformed or non-transformed 25(OH)D 468 
concentrations, see Supplementary Table 2), in practice a 20nmol/Liter increase is more 469 
likely to make an impact on women with low 25(OH)D concentrations than those whose 470 
concentration is already high.  471 
 472 
In our main analysis, there were concerns that the effect of the GC SNP on 25(OH)D 473 
was not estimated with high accuracy (GC SNP estimates were based on 2 347 individuals 474 
[26] whereas the estimates for DHCR7 and CYP2R1 were derived based on 30 792 475 
individuals [31]), as well as concerns that the GC SNP may not influence in 25-476 
hydroxyvitamin D’s biological activity in a predictable way [31, 38, 39]. Nonetheless, we 477 
conducted a sensitivity analyses to examine the effect of excluding this SNP. When the GC 478 
SNP was excluded, our results were unchanged (the association with ovarian cancer of the 479 
combined effect of the 3 SNPs was very similar to that obtained using just 2 SNPs, see 480 
Supplementary Table 5). 481 
 482 
Another potential limitation of our analysis is residual pleiotropy.  We found no 483 
evidence for SNP-confounder association based on the subset of participants with available 484 
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confounder information (Supplementary Table 6) although we cannot rule out associations 485 
with unmeasured confounders. Approach such as Egger regression [40] can potentially be 486 
applied to further test the MR assumptions but these require more SNPs than the two 487 
employed here. 488 
 489 
Interpretation of findings 490 
Observation of a larger magnitude of association (OR=1.54) with high grade serous cancer 491 
for lower 25(OH) concentration suggests that the association of circulating 25(OH)D with 492 
risk of ovarian cancer may be confined to the high grade serous type, although the 493 
confidence limits of the two ORs are overlapping and high-grade serous cancer is contained 494 
within all ovarian cancer. The results for histological subtypes other than high grade serous 495 
carcinoma are shown in Figure 3 (for association of each individual SNP, see Supplementary 496 
Table 3), and there is no evidence for association for non-serous disease. For all non high-497 
grade serous cancers combined, the odds ratio was 1.12 (0.89-1.41). 498 
 499 
  The association of lower circulating vitamin D (25(OH)D) levels to risk of epithelial 500 
ovarian cancer appear to be consistent with a recent MR study [31] looking at all-cancer 501 
mortality. Vitamin D activating enzymes and vitamin D receptors are present in many 502 
tissues, with the regulation of 1-3% of gene expression in these tissues attributable to 503 
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vitamin D [35]. Studies have also shown that vitamin D is involved in the regulation of cell 504 
processes (proliferation, differentiation and apoptosis) in several cell types that are central 505 
to the development of cancer [14, 41-43]. Thus, our findings warrant further investigations 506 
on the biological role of vitamin D (specifically, 25(OH)D) in mortality as well as risk of 507 
ovarian cancer. 508 
  509 
  In conclusion, we demonstrate an association between low 25(OH)D concentration 510 
and risk of ovarian cancer in women of European ancestry, with our MR approach providing 511 
estimates which are unaffected by the confounding or biases present in observational 512 
studies. Whilst our results cannot guarantee causality, placed in the context of other 513 
epidemiological studies, they provide additional evidence supportive of a causal link 514 
between vitamin D and risk of ovarian cancer. 515 
 516 
 517 
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Table 1: Distribution of cases based on epithelial ovarian carcinoma subtypes 
EOC subtypes Number of Cases 
High-grade Serous  4 121 
Low-grade Serous 363 
Serous of unknown grade 1 344 
Mucinous 662 
Clear Cell 621 
Endometroid 1 350 
Others 1 604 
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Table 2: Mendelian randomization results: 25(OH)D concentration and ovarian cancer. 
SNPs EA/NEA 25(OH)D per 25(OH)D decreasing 
allele (nmol/Liter) 
All epithelial ovarian subtype 
(N=10 065 cases) 
Only high grade serous epithelial ovarian subtype 
(N=4 121 cases) 
   
   	
 	
   	
 	
 
rs7944926 A/G -2 0.19 0.40% 0.0153 0.0217 -0.0076 0.0109 0.0418 0.0309 -0.0209 0.0154 
rs12794714 A/G -3 0.22 0.60% 0.0412 0.0189 -0.0137 0.0063 0.0772 0.0270 -0.0257 0.0091 
rs2282679 C/A -2.5 0.70 0.30% 0.0276 0.0205 -0.0110 0.0082 0.0432 0.0292 -0.0173 0.0117 
Combined - - - 1.30% - - -0.0118 0.0045 - - -0.0218 0.0067 
 
EA/NEA refers to the Effect Allele and Non-Effect Allele. 
 	denotes the magnitude of association of the SNP-outcome estimate.  
 is the standard error of the SNP-exposure estimate. 
  denotes the magnitude of association of Z, the SNP instrument on X, the modifiable exposure level (25(OH)D). 
 is the standard error of .  
R
2
 is the proportion of variance in 25(OH)D explained by the SNP(s).  
	
  is the estimate and 	
  its standard deviation.  is presented on the log(OR) scale.  
	
  is presented on the log(OR) scale for a single unit (1nmol/Liter) change in 25(OH)D – see text for OR scale changes for a 20 unit (nmol/Liter) change in 25(OH)D. 
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Note: the   estimate for rs2282679 is obtained from Mokry et al. and transformed to natural scale (from natural logarithm) using an intercept at 
 (~54.59) nmol/Litre 
of 25(OH)D. Standard errors for these estimates were calculated from F-statistics. The variance explained () for rs12794714 and rs7944926 were obtained directly from 
Afzal et al. ; whereas the  for rs2822679 was computed from Mokry et al. 
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Schematic representation of the Mendelian randomization framework using vitamin D SNPs as instrumental 
variables.  
750x292mm (96 x 96 DPI)  
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Causal OR of 25(OH)D on all ovarian cancer and high grade serous ovarian cancer  
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Causal OR of 25(OH)D on individual ovarian cancer subtypes  
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